Drug updated on 4/16/2024
| Dosage Form | Injection (intravenous: 400 mg) |
| Drug Class | Lipoglycopeptide antibacterials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.
Summary
- Oritavancin (Orbactiv) is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. It has demonstrated efficacy in multidose regimens, treating various Gram-positive infections beyond ABSSSIs, including osteomyelitis and cellulitis.
- Studies including systematic reviews, meta-analyses, and comparative studies provide a wide scope of data relating to the clinical use, safety profile, and effectiveness of Orbactiv compared to other antibiotics used in similar indications.
- The drug shows potent in vitro activity against MRSA isolates. Its MIC50 and MIC90 values are slightly lower than those for dalbavancin, tedizolid, and telavancin, indicating strong efficacy against MRSA infections.
- In terms of intracellular S. aureus infection treatments, such as osteomyelitis cases where some antibiotics struggle with intracellular penetration, oritavancin stands out as one of the most effective options.
- Regarding safety profiles during ABSSSIs treatment, Orbactiv was found non-inferior when compared with other comparator antibiotics, significantly reducing 30-day readmission rates along with drug-related adverse events. This makes it an ideal choice, especially in outpatient settings, due to its potential reduction in hospital readmission rate.
- A comparison between vancomycin plus novel glycopeptides versus oritavancin showed no significant differences regarding their efficacies, but fewer adverse events were associated with Orbactiv (and dalbavancin), positioning them as safer alternatives for gram-positive bacterial infection treatments.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Orbactiv (oritavancin) prescribing information. | 2022 | Melinta Therapeutics LLC, Lincolnshire, IL |